These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

206 related articles for article (PubMed ID: 26415869)

  • 1. Mastering variation: variance components and personalised medicine.
    Senn S
    Stat Med; 2016 Mar; 35(7):966-77. PubMed ID: 26415869
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Personalized treatment selection using data from crossover designs with carry-over effects.
    Siriwardhana C; Kulasekera KB; Datta S
    Stat Med; 2019 Dec; 38(28):5391-5412. PubMed ID: 31637762
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Subgroup analysis with semiparametric models toward precision medicine.
    Yuan A; Chen X; Zhou Y; Tan MT
    Stat Med; 2018 May; 37(11):1830-1845. PubMed ID: 29575056
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Using pilot data to size a two-arm randomized trial to find a nearly optimal personalized treatment strategy.
    Laber EB; Zhao YQ; Regh T; Davidian M; Tsiatis A; Stanford JB; Zeng D; Song R; Kosorok MR
    Stat Med; 2016 Apr; 35(8):1245-56. PubMed ID: 26506890
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Biomarker threshold adaptive designs for survival endpoints.
    Diao G; Dong J; Zeng D; Ke C; Rong A; Ibrahim JG
    J Biopharm Stat; 2018; 28(6):1038-1054. PubMed ID: 29436940
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The benefit of stratification in clinical trials revisited.
    Ganju J; Zhou K
    Stat Med; 2011 Oct; 30(24):2881-9. PubMed ID: 21905064
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Analysis of Poisson frequency data under a simple crossover trial.
    Lui KJ; Chang KC
    Stat Methods Med Res; 2016 Feb; 25(1):385-99. PubMed ID: 22899697
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A note on misspecification in general linear models with correlated errors for the analysis of crossover clinical trials.
    Wang W; Cong N; Chen T; Zhang H; Zhang B
    PLoS One; 2019; 14(3):e0213436. PubMed ID: 30870443
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Some methods for heterogeneous treatment effect estimation in high dimensions.
    Powers S; Qian J; Jung K; Schuler A; Shah NH; Hastie T; Tibshirani R
    Stat Med; 2018 May; 37(11):1767-1787. PubMed ID: 29508417
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Enhanced precision in the analysis of randomized trials with ordinal outcomes.
    Díaz I; Colantuoni E; Rosenblum M
    Biometrics; 2016 Jun; 72(2):422-31. PubMed ID: 26576013
    [TBL] [Abstract][Full Text] [Related]  

  • 11. IDENTIFICATION OF QUESTIONABLE EXCLUSION CRITERIA IN MENTAL DISORDER CLINICAL TRIALS USING A MEDICAL ENCYCLOPEDIA.
    Ma H; Weng C
    Pac Symp Biocomput; 2016; 21():219-30. PubMed ID: 26776188
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Efficient design and inference for multistage randomized trials of individualized treatment policies.
    Dawson R; Lavori PW
    Biostatistics; 2012 Jan; 13(1):142-52. PubMed ID: 21765180
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Weighted win loss approach for analyzing prioritized outcomes.
    Luo X; Qiu J; Bai S; Tian H
    Stat Med; 2017 Jul; 36(15):2452-2465. PubMed ID: 28343373
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Statistical tests based on new composite hypotheses in clinical trials reflecting the relative clinical importance of multiple endpoints quantitatively.
    Nishikawa M; Tango T; Ohtaki M
    Biom J; 2009 Oct; 51(5):749-62. PubMed ID: 19777463
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Treatment evaluation for a data-driven subgroup in adaptive enrichment designs of clinical trials.
    Zhang Z; Chen R; Soon G; Zhang H
    Stat Med; 2018 Jan; 37(1):1-11. PubMed ID: 28948633
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Tutorial in biostatistics: data-driven subgroup identification and analysis in clinical trials.
    Lipkovich I; Dmitrienko A; B R
    Stat Med; 2017 Jan; 36(1):136-196. PubMed ID: 27488683
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Measurement in clinical trials: a neglected issue for statisticians?
    Senn S; Julious S
    Stat Med; 2009 Nov; 28(26):3189-209. PubMed ID: 19455540
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Using decision lists to construct interpretable and parsimonious treatment regimes.
    Zhang Y; Laber EB; Tsiatis A; Davidian M
    Biometrics; 2015 Dec; 71(4):895-904. PubMed ID: 26193819
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Simple subgroup approximations to optimal treatment regimes from randomized clinical trial data.
    Foster JC; Taylor JM; Kaciroti N; Nan B
    Biostatistics; 2015 Apr; 16(2):368-82. PubMed ID: 25398774
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Interim treatment selection with a flexible selection margin in clinical trials.
    Wu Y; Zhao PL
    Stat Med; 2013 Jul; 32(15):2529-43. PubMed ID: 23212767
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.